Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

NCT05392946 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Plasma Cell Myeloma

Interventions

DRUG: Bortezomib
BIOLOGICAL: Daratumumab
DRUG: Dexamethasone
DRUG: Iberdomide

Sponsor

Mayo Clinic